Wegovy Pill – Compliance Alert

Caution

This ad has patterns previously flagged by FDA.

Analysis of this 75s ad identified 2 enforcement patterns, primarily Efficacy. Patterns span Visual Distraction, Efficacy — “Family & Social Scenes” identified at 40.1s, previously cited in Jardiance (x3), Contrave, Qulipta. FDA enforcement letter on file dated Feb 5, 2026.

Recommended action: Initiate PromoMats review: Verify all efficacy claims against current approved labeling. Visual representations should align with clinical trial results referenced in the PI.

Video Timeline

Risk disclosure: 24.8s – 66.0s (41.2s of 75.2s total — 54.7% of ad)

Risk Window

0s19s38s56s75s

Family & Social?Risk Window?

Patterns Detected (2)

Each pattern below is a known FDA enforcement concern, identified by matching this ad against 14 violation types from 34 FDA warning letters

Pattern	Dimension	Score	Evidence	CFR
Family & Social Scenes Warm family scenes that emotionally minimize risk information	Visual Distraction	73	2 clips	21 CFR 202.1(e)(1)	▶
FDA Concern: Risk information must be presented in a clear, conspicuous, and neutral manner without distracting visuals Previously cited: Jardiance (x3), Contrave, Qulipta, Calquence, Austedo (x2)
Dramatic Before/After Before/after visuals that may overstate treatment outcomes	Efficacy	61		21 CFR 202.1(e)(5)	▶
FDA Concern: Advertisements cannot be false or misleading in any particular Previously cited: TURALIO, TREMFYA

Recommendations

high

Initiate PromoMats review: Verify all efficacy claims against current approved labeling. Visual representations should align with clinical trial results referenced in the PI.

high

Escalate to regulatory affairs: FDA enforcement letter on file (Feb 5, 2026). Verify remediation status in PromoMats and confirm all content modifications address cited violations before next distribution.

Compliance Alert: Wegovy Pill

Recommendations